Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Shuchi S. Pandya"'
Autor:
Ingo K. Mellinghoff, Min Lu, Patrick Y. Wen, Jennie W. Taylor, Elizabeth A. Maher, Isabel Arrillaga-Romany, Katherine B. Peters, Benjamin M. Ellingson, Marc K. Rosenblum, Saewon Chun, Kha Le, Ania Tassinari, Sung Choe, Youssef Toubouti, Steven Schoenfeld, Shuchi S. Pandya, Islam Hassan, Lori Steelman, Jennifer L. Clarke, Timothy F. Cloughesy
Publikováno v:
Nature medicine, vol 29, iss 3
Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against mIDH glioma. We evaluated both agents in a perioperative phase 1 trial to explore the mechanism of action in recur
Autor:
Gerald Edelman, Coumaran Egile, Yi Xu, Linh T. Nguyen, A. Douglas Laird, Christian Scheffold, Shuchi S. Pandya, Irene Braña, Jose Baselga, Eunice L. Kwak, Cynthia Bedell, Jordi Rodon, Geoffrey I. Shapiro
PDF file - 1641K, Effect of SAR245408 on plasma fasting insulin and glucose.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b19731350a0d5e36474ba801261994e
https://doi.org/10.1158/1078-0432.22448138
https://doi.org/10.1158/1078-0432.22448138
Autor:
Gerald Edelman, Coumaran Egile, Yi Xu, Linh T. Nguyen, A. Douglas Laird, Christian Scheffold, Shuchi S. Pandya, Irene Braña, Jose Baselga, Eunice L. Kwak, Cynthia Bedell, Jordi Rodon, Geoffrey I. Shapiro
Purpose: SAR245408 is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor. This phase I study determined the maximum tolerated dose (MTD) of two dosing schedules [first 21 days of a 28-day period (21/7) and continuous once-daily dosing (CDD)], p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a5e38c4408d79c7172f3dce9e32bde3
https://doi.org/10.1158/1078-0432.c.6521315
https://doi.org/10.1158/1078-0432.c.6521315
Autor:
Gerald Edelman, Coumaran Egile, Yi Xu, Linh T. Nguyen, A. Douglas Laird, Christian Scheffold, Shuchi S. Pandya, Irene Braña, Jose Baselga, Eunice L. Kwak, Cynthia Bedell, Jordi Rodon, Geoffrey I. Shapiro
PDF file - 73K, Safety of SAR245408.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e96a2757bccb5d1d8d4f490f8b82d86
https://doi.org/10.1158/1078-0432.22448126
https://doi.org/10.1158/1078-0432.22448126
Autor:
Gerald Edelman, Coumaran Egile, Yi Xu, Linh T. Nguyen, A. Douglas Laird, Christian Scheffold, Shuchi S. Pandya, Irene Braña, Jose Baselga, Eunice L. Kwak, Cynthia Bedell, Jordi Rodon, Geoffrey I. Shapiro
PDF file - 96K, Reduction in PI3K pathway signaling in serial tumor biopsies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::886c57517348f73a216889214dab1bad
https://doi.org/10.1158/1078-0432.22448120.v1
https://doi.org/10.1158/1078-0432.22448120.v1
Autor:
Gerald Edelman, Coumaran Egile, Yi Xu, Linh T. Nguyen, A. Douglas Laird, Christian Scheffold, Shuchi S. Pandya, Irene Braña, Jose Baselga, Eunice L. Kwak, Cynthia Bedell, Jordi Rodon, Geoffrey I. Shapiro
PDF file - 6224K, Inhibition of MEK-ERK pathway signaling in tumor biopsies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79aa092fb8f6804b8fc0efc97b0f84e7
https://doi.org/10.1158/1078-0432.22448135
https://doi.org/10.1158/1078-0432.22448135
Autor:
Gerald Edelman, Coumaran Egile, Yi Xu, Linh T. Nguyen, A. Douglas Laird, Christian Scheffold, Shuchi S. Pandya, Irene Braña, Jose Baselga, Eunice L. Kwak, Cynthia Bedell, Jordi Rodon, Geoffrey I. Shapiro
PDF file - 91K, Anti-tumor activity in patients receiving treatment more than 16 weeks.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abfd2869bfe2535ea7eec14f01d5ef52
https://doi.org/10.1158/1078-0432.22448117.v1
https://doi.org/10.1158/1078-0432.22448117.v1
Autor:
Gerald Edelman, Coumaran Egile, Yi Xu, Linh T. Nguyen, A. Douglas Laird, Christian Scheffold, Shuchi S. Pandya, Irene Braña, Jose Baselga, Eunice L. Kwak, Cynthia Bedell, Jordi Rodon, Geoffrey I. Shapiro
PDF file - 74K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0124b3972525122f105c19b524130429
https://doi.org/10.1158/1078-0432.22448132
https://doi.org/10.1158/1078-0432.22448132
Autor:
Gerald Edelman, Coumaran Egile, Yi Xu, Linh T. Nguyen, A. Douglas Laird, Christian Scheffold, Shuchi S. Pandya, Irene Braña, Jose Baselga, Eunice L. Kwak, Cynthia Bedell, Jordi Rodon, Geoffrey I. Shapiro
PDF file - 458K, Individual and mean SAR245408 pharmacokinetic parameters.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::644dbc372a5a343629808b116de1f502
https://doi.org/10.1158/1078-0432.22448141.v1
https://doi.org/10.1158/1078-0432.22448141.v1
Autor:
Michael B. Atkins, Shuchi S. Pandya, Matthew L. Sherman, Kenneth M. Attie, Chad Glasser, Musa Mutyaba, Xiaosha Zhang, Dawn Wilson, J. Thaddeus Beck, Robert S. Alter, Brian I. Rini, Elizabeth R. Plimack, Rupal S. Bhatt, Martin H. Voss
Supplemental data for DART Part 1 manuscript. Contains 1 figure and 3 tables. Supplemental Figure 1: Percent change from baseline in serum receptor expression. Samples were taken at cycle 1 day 1 (baseline), cycle 2 day 1, cycle 2 day 8, cycle 3 day
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::410f0f76cebadf9114b7e1c3fa4fa5c6
https://doi.org/10.1158/1078-0432.22466726.v1
https://doi.org/10.1158/1078-0432.22466726.v1